Altogen Labs

Cancer remains one of the most complex and urgent health challenges of our time. At Altogen Labs, we are proud to contribute to innovative approaches that push the boundaries of targeted cancer therapy. The April 2021 OncoLife Therapeutics slide deck features our role in supporting preclinical studies of antisense oligonucleotide (A*O) therapeutics targeting hepatocellular carcinoma (HCC), a devastating form of liver cancer.
The research focuses on identifying small genetic differences between cancer and healthy stem cells—a strategy that promises greater therapeutic precision and less systemic toxicity. To support this breakthrough approach, Altogen Labs conducted efficacy studies in HepG2 liver cancer models, evaluating several A*O candidates over a six-week treatment course. These studies generated critical data on tumor growth inhibition, therapeutic response, and compound tolerability. Our In Vivo Safety Toxicology services further ensured that emerging candidates demonstrated promising safety profiles prior to clinical advancement.
This collaboration reflects the broader importance of preclinical oncology platforms that can predict translational outcomes and optimize therapeutic strategy. Altogen Labs remains a committed partner in oncology drug development, offering validated xenograft models and full-spectrum biology CRO services.
To explore our services, visit: https://altogenlabs.com/xenograft-models/

Xenotransplantation has emerged as a vital research strategy in cancer and regenerative medicine, and we’re proud to be cited in a review article titled “Xenotransplantation – A Review,” published in the World Journal of Pharmaceutical Research.

The article discusses the application of xenografts—transplants between species—as a research method, including the transplantation of human tumor cells into immunocompromised mice. This approach plays a crucial role in oncology drug development, allowing researchers to assess tumor growth, treatment response, and molecular mechanisms in vivo.

Altogen Labs was cited for providing xenograft animal models in preclinical research. With over 100 validated tumor xenograft systems, Altogen Labs enables pharmaceutical companies and academic researchers to accelerate drug discovery and translational studies.

To explore our xenograft services, visit:

Xenograft Models - Altogen Labs Altogen Labs in-house validated xenograft models (CDX and PDX; mouse and rat models): Tumor type: Altogen Labs in-house validated xenograft models: Brain LN229 , SF268 , SF295 , A172 , SF539 , SK-N-AS , SNB-19 , SNB-75 , U-251 MG , U87 MG , U118 , U87-Luc Breast Cancer 4T1 , BT474 , CAL51 , HS578T ,...

How do mechanical properties of glioblastoma cells affect tumor growth and therapy resistance? A 2025 Scientific Reports study titled “Exploring the heterogeneity in glioblastoma cellular mechanics using in-vitro assays and atomic force microscopy” addresses this emerging question using advanced biophysical tools.

The authors applied atomic force microscopy to characterize differences in stiffness and deformability across glioblastoma subtypes, using U87 as a representative model. Their findings highlight that mechanical phenotyping may be a useful tool for understanding glioblastoma heterogeneity and guiding treatment decisions.

Altogen Labs was cited for its U87 Xenograft Model, which has long served as a foundational platform for glioblastoma drug development and preclinical evaluation.

To learn more about our U87 xenograft model and other brain tumor services, visit:
https://altogenlabs.com/xenograft-models/

Cell lines are the foundation of cancer research—but without consistent documentation and authentication, they can compromise data integrity and reproducibility. A new article published in NPJ Precision Oncology, titled “Research reporting guidelines for cell lines: more than just a recommendation,” proposes urgently needed reforms to how cell line experiments are reported in biomedical research.

Altogen Labs is cited in this publication for its SMMC-7721 liver cancer xenograft model, which was highlighted as an example of a well-documented and standardized in vivo model. The SMMC-7721 model is used in numerous preclinical oncology programs and supports the development of therapies targeting hepatocellular carcinoma.

We’re proud to contribute to global efforts in reproducibility, transparency, and the responsible use of biological models in oncology.

Learn more about our SMMC-7721 and other validated xenograft tumor models here:

Xenograft Models - Altogen Labs Altogen Labs in-house validated xenograft models (CDX and PDX; mouse and rat models): Tumor type: Altogen Labs in-house validated xenograft models: Brain LN229 , SF268 , SF295 , A172 , SF539 , SK-N-AS , SNB-19 , SNB-75 , U-251 MG , U87 MG , U118 , U87-Luc Breast Cancer 4T1 , BT474 , CAL51 , HS578T ,...